In this article, we’ll take an in-depth look at the top 10 insider purchases last month. Previously, we covered the 10 stocks with the most insider purchases in the last quarter.
Will there be a recession? How will new tariffs impact the U.S. economy? What’s next on President Trump’s geopolitical agenda? These are some of the concerning questions influencing market conditions.
According to J.P. Morgan’s chief global economist, Bruce Kasman, there is about a 40% chance of a U.S. recession and a risk of lasting damage to the country’s reputation as an investment destination, writes Reuters.
“Where we stand now is with a heightened concern about the U.S. economy,” Kasman said to reporters in Singapore on Wednesday.
Additionally, Goldman Sachs lowered its 2025-end target for the broader market. “The proximate causes of the market decline are the jump in policy uncertainty largely related to tariffs, concerns about the economic growth outlook, and a positioning unwind, especially among hedge funds,” analysts at Goldman Sachs wrote in a Monday note.
The experts further explained that the drop in a broader market index was mostly driven by a 14% drop in the share prices of the “Magnificent 7” stocks.
As the market responds to evolving political and economic changes, some analysts remain optimistic, particularly when it comes to the growth potential of AI technology. During these times, insider trading often captures attention, as company executives have valuable insights into their organizations. For instance, when a CEO or CFO buys company stock, it can indicate a positive outlook on the business’s future.
On the other hand, insider selling isn’t necessarily a sign of a lack of confidence, as it may stem from personal financial considerations or efforts to diversify portfolios. Executives frequently execute these transactions through pre-established plans (such as 10b5-1 plans), which are designed to avoid any appearance of improper timing.
While insider activity can offer useful signals, it’s important to consider it in the context of other factors, such as the company’s financial performance, market trends, and industry developments.
An aerial view of trading terminals and monitors, displaying markets from around the world.
Our Methodology
In this report, we’ll focus on the stocks that insiders spent the most money on in February. Using Insider Monkey’s insider trading screener, we’ve identified stocks where at least three insiders acquired shares last month. From this group, we’ve highlighted the 10 stocks with the highest value of insider purchases.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
For each stock, we provide details on the total value of insider purchases and the company’s current market capitalization. Let’s take a look at the top 10 insider purchases from last month.
10. Septerna, Inc. (NASDAQ:SEPN)
Total value of insider purchases in February: $6,606,649.32
Market capitalization: $296.17 million
We begin the list with Septerna, a clinical-stage biotech based in South San Francisco, California. The company is developing G protein-coupled receptor (GPCR) oral small molecule product candidates. It is also one of the 10 stocks with at least $30 million in insider spending recently.
Septerna focuses on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
In February, three insiders bought a combined total of $6.61 million in Septerna shares at an average price of $5.79 per share. Currently, the stock trades at $6.55 per share, having lost 71.40% year-to-date. Since its IPO in October, Septerna shares declined 69.39%.
Four analysts have assigned a ‘Buy’ rating to Septerna stock, with a 12-month price target of $34.00, representing a potential upside of 420.67%, writes StockAnalysis.
9. OncoCyte Corporation (NASDAQ:OCX)
Total value of insider purchases in February: $12,998,805.30
Market capitalization: $113.11 million
OncoCyte Corporation is a precision diagnostics company dedicated to developing innovative, non-invasive blood and urine tests for the early detection of cancer. Based in Irvine, California, the company creates diagnostic solutions by utilizing genetic and protein markers associated with various forms of cancer.
The company’s flagship tests include VitaGraft, a clinical blood-based test for monitoring solid organ transplantation; GraftAssure, a research-use-only blood test for the same purpose; DetermaIO, a gene expression test that evaluates the tumor microenvironment to predict responses to immunotherapy; and DetermaCNI, a blood-based tool for monitoring therapeutic efficacy in cancer patients.
In February, three insiders bought a total of nearly $13 million worth of OncoCyte Corporation shares at an average price of $2.04 per share. Year-to-date, the stock has gained 65.13% and is now priced at $3.93 per share. Over the past 12 months, its shares have risen by 30.56%.
According to three analysts’ assessments, OncoCyte stock is a “Moderate Buy” with a price target of $4.42, writes MarketBeat.
8. Arcus Biosciences, Inc. (NYSE:RCUS)
Total value of insider purchases in February: $15,402,661.00
Market capitalization: $1.01 billion
Arcus Biosciences is a clinical-stage biopharmaceutical company engaged in the development of best-in-class molecules and combination therapies for cancer patients. Among the company’s leading candidates are Domvanalimab, an anti-TIGIT antibody currently in Phase 2 and Phase 3 clinical trials, and AB308, an investigational anti-TIGIT monoclonal antibody in a Phase 1b clinical trial studying patients with advanced solid and hematologic malignancies. TIGIT is a checkpoint protein found on immune cells in the tumor microenvironment that inhibits the immune system’s natural ability to detect and kill cancer cells.
In February, three insiders acquired a total of $15.40 million worth of Arcus shares at an average price of $10.41 per share. Currently, the stock is trading at $9.46 per share, having lost 36.47% year-to-date, and 49.25% over the past 12 months.
Ten analysts have rated Arcus stock as “Buy” and projected a price of $30.25, according to MarketBeat. The average price target represents a forecasted upside of 219.16% from the latest price.
7. Aardvark Therapeutics, Inc. Common Stock (NASDAQ:AARD)
Total value of insider purchases in February: $23,424,672.00
Market capitalization: $218.12 million
Seventh among 10 stocks with the highest value of insider purchases in February is a clinical-stage biopharma company Aardvark Therapeutics. The San Diego, California-based company is dedicated to developing small-molecule therapies aimed at activating innate homeostatic pathways to address metabolic disorders.
The company’s lead product, ARD-101, is designed to target receptors found on enteroendocrine cells in the gut lumen, which play a vital role in gut-brain signaling. ARD-101 is currently in Phase III trials for treating hyperphagia associated with Prader-Willi Syndrome and Phase II trials for hyperphagia linked to acquired hypothalamic obesity.
Aardvark went public in February, and during its IPO, four insiders bought a total of $23.42 million worth of Aardvark shares at a price of $16 per share. Since then, its shares lost 28.72% and the stock is now trading at $10.20 per share.
Four analysts have given Aardvark stock an average rating of “Strong Buy,” writes StockAnalysis. The 12-month price target is set at $30.50.
6. Solid Biosciences Inc. (NASDAQ:SLDB)
Total value of insider purchases in February: $26,089,240.20
Market capitalization: $437.36 million
Solid Biosciences is a life sciences company based in Charleston, Massachusetts, focused on developing therapies for neuromuscular and cardiac diseases in the U.S. The company has several promising product candidates in its pipeline, including SGT-003, a gene transfer therapy for Duchenne muscular dystrophy, and SGT-501, designed to treat Catecholaminergic polymorphic ventricular tachycardia.
In February, Solid Biosciences announced promising initial data from the Phase 1/2 INSPIRE DUCHENNE trial of SGT-003. Interim 90-day biopsy results from the first three participants revealed an average microdystrophin expression of 110%, measured by western blot, along with improvements in several biomarkers indicative of muscle health and resilience.
Also in February, three insiders acquired a total of $26.09 million worth of Solid Biosciences shares at an average price of $5.21 per share. Year-to-date, the stock gained 40.38% and is now trading at $5.62 per share. Over the past 12 months, Solid Biosciences shares declined 50.75%.
Based on assessments from 12 analysts, Solid Biosciences stock has an average rating of “Strong Buy,” with a price target of $18.17, according to StockAnalysis. The average price target indicates an upside of 224.46% from the latest price.
5. CompoSecure, Inc. (NASDAQ:CMPO)
Total value of insider purchases in February: $41,544,359.58
Market capitalization: $1.1 billion
In the middle of this list of the top 10 insider purchases last month is CompoSecure, a designer and manufacturer of advanced metal, composite, and proprietary financial transaction cards. The Franklin Township, New Jersey-based company is focused on cutting-edge payment card technology, including metal cards equipped with Arculus security and authentication features. Its offering also includes Arculus Cold Storage Wallet, a three-factor authentication solution, which supports specific digital assets, including Bitcoin, Ethereum, non-fungible tokens and others.
In February, three insiders purchased a total of $41.54 million worth of CompoSecure shares at a price of $15.73 per share. Since the beginning of the year, the stock lost 14.61% and is now trading at $10.87 per share. However, over the past 12 months, CompoSecure returned 119.60% to its investors.
Six Wall Street analysts have given an average “Strong Buy” rating on CompoSecure stock, according to TipRanks. The average price target is $15.
4. Sionna Therapeutics, Inc. (NASDAQ:SION)
Total value of insider purchases in February: $62,460,000.00
Market capitalization: $730.22 million
A biopharmaceutical company, Sionna Therapeutics, is also among the 10 stocks insiders are buying this year. The Waltham, Massachusetts-headquartered company is engaged in the development of new treatments for cystic fibrosis (CF). Its founders have more than a decade of research in the area and are leading the company to develop new therapeutics that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients.
Sionna went public in February, and six insiders decided to take part in the offering by buying a total of around $62.46 million worth of Sionna shares at a price of $18 per share. Since its IPO, Sionna stock lost 33.60% and is now trading at $16.60 per share.
Three analysts have given an average “Buy” rating to Sionna stock, with a 12-month price target of $38.50, according to MarketBeat. The average price target suggests a potential upside of 132.91% from the latest price.
3. Metsera, Inc. (NASDAQ:MTSR)
Total value of insider purchases in February: $94,219,956.00
Market capitalization: $2.64 billion
The third among the stocks with the highest value of insider purchases in February is a clinical-stage biotechnology company, Metsera. The New York City-based company is developing injectable and oral nutrient-stimulated hormone analog peptides to treat obesity and metabolic diseases. It was founded in 2022 by Population Health Partners and ARCH Venture Partners.
In January, the company shared promising results from a 12-week Phase 2a clinical trial of its leading drug candidate, MET-097i, which is being developed as a potential once-monthly injectable treatment for obesity. The trial showed that MET-097i led to significant weight loss in participants, with some shedding up to 20% of their body weight, and was generally well tolerated, with only mild side effects. The company intends to conduct additional studies in 2025.
The company went public at the beginning of February. During its IPO, three insiders purchased a total of $94.22 million worth of Metsera shares at a price of $18 per share. Since then, the stock gained 4.40% and is now trading at $25.34 per share.
Based on assessments from four analysts, Metsera stock has an average rating of “Strong Buy,” writes StockAnalysis. The 12-month price target is $47.00, representing an anticipated increase of 85.88% from its current price.
2. Amkor Technology, Inc. (NASDAQ:AMKR)
Total value of insider purchases in February: $94,999,976.00
Market capitalization: $4.77 billion
Amkor provides outsourced semiconductor packaging and testing services across the U.S., Japan, Europe, and the Asia Pacific region. Its offering includes professional packaging and testing services, such as semiconductor wafer bump, wafer probe, wafer back-grind, package design, packaging, system-level and final testing, and more. The company, based in Tempe, Arizona, is also among the 12 stocks with heavy insider buying in 2025.
In February, five insiders bought a total of close to $95 million worth of Amkor Technology shares at a price of $21.85 per share. Year-to-date, the stock declined 24.39% and is now trading at $19.43 per share. Over the past 12 months, its shares lost 42.92%.
For the full year of 2024, the company reported net sales of $6.32 billion, compared to $6.50 billion in 2023. Net income attributable to Amkor amounted to $354 million, or $1.43 per diluted share, compared to $360 million, or $1.46 per diluted share, in the prior year.
According to eight analysts, Amkor stock is a “Buy,” reports StockAnalysis. The average price target is $31.71, suggesting a 63.33% upside.
1. TKO Group Holdings, Inc. (NYSE:TKO)
Total value of insider purchases in February: $447,604,781.43
Market capitalization: $12.01 billion
The stock that had the top insider purchases last month is a very well-known global sports and entertainment company – TKO Group. The Stamford, Connecticut-headquartered company produces and licenses a variety of content, including live events, TV programs, reality series, and both long- and short-form content. Its content reaches over 1 billion households in approximately 210 countries and territories. Each year, TKO Group organizes more than 300 live events, drawing in over two million fans.
TKO Group was formed by Endeavor (NYSE:EDR) through a merger between World Wrestling Entertainment and Zuffa, LLC, the parent company of the Ultimate Fighting Championship.
In February, three insiders, among which is the company’s CEO, acquired a total of around $447.61 million worth of TKO Group shares at an average price of $166.99 per share. Currently, the stock is trading at $147.29 per share, having gained 3.65% since the beginning of the year. Over the past 12 months, TKO Group returned 81.21% to its investors.
Thirteen analysts have given a “Strong Buy” rating to TKO Group stock, with a price target of $178.36, writes TipRanks.
Overall, TKO ranks first among the top 10 insider purchases last month. While we acknowledge the potential of TKO, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TKO but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
